vTv Therapeutics Inc. (VTVT) Stock Rating Reaffirmed by Piper Jaffray Cos.
vTv Therapeutics Inc. (NASDAQ:VTVT)‘s stock had its “overweight” rating reiterated by analysts at Piper Jaffray Cos. in a note issued to investors on Saturday. They presently have a $24.00 price objective on the stock. Piper Jaffray Cos.’s target price would suggest a potential upside of 243.35% from the company’s current price.
Several other equities research analysts have also weighed in on VTVT. HC Wainwright started coverage on vTv Therapeutics in a report on Monday, September 26th. They issued a “buy” rating and a $13.00 target price for the company. Canaccord Genuity restated a “buy” rating and issued a $15.00 target price on shares of vTv Therapeutics in a report on Friday, August 19th. Finally, Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.00.
vTv Therapeutics (NASDAQ:VTVT) traded up 5.27% during mid-day trading on Friday, hitting $6.99. 19,107 shares of the stock were exchanged. The company’s market cap is $67.73 million. vTv Therapeutics has a one year low of $4.84 and a one year high of $8.22. The company has a 50-day moving average price of $6.57 and a 200-day moving average price of $5.94.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, analysts predict that vTv Therapeutics will post ($1.61) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of vTv Therapeutics by 4.1% in the second quarter. Vanguard Group Inc. now owns 288,146 shares of the company’s stock valued at $1,671,000 after buying an additional 11,428 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of vTv Therapeutics by 26.6% in the second quarter. BlackRock Fund Advisors now owns 202,202 shares of the company’s stock valued at $1,173,000 after buying an additional 42,520 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of vTv Therapeutics by 17.2% in the second quarter. Ameriprise Financial Inc. now owns 161,484 shares of the company’s stock valued at $936,000 after buying an additional 23,705 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock valued at $559,000 after buying an additional 18,112 shares in the last quarter. Finally, State Street Corp increased its position in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock valued at $488,000 after buying an additional 22,983 shares in the last quarter. 12.84% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.